Results 91 to 100 of about 19,791 (259)

Bromelain as the enzyme of the future: A global bibliometric mapping of its applications and emerging trends

Journal of the Science of Food and Agriculture, EarlyView.
Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto, Tonny Cley Campos Leite, Mônica Tejo Cavalcanti, Geany Targino Sousa Pedrosa, Rerisson do Nascimento Alves, Amanda Reges de Sena, Mônica Correia Gonçalves   +6 more
wiley   +1 more source

Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor?

Case Reports in Gastroenterology
Introduction: Recent-onset colitis poses a diagnostic challenge, necessitating a thorough evaluation to identify potential infectious and non-infectious etiologies.
Ahmed B. Bayoumy, Gwen M.C. Masclee, Nanne K.H. de Boer, Andra Neefjes-Borst, Dirk Jan Stenvers   +4 more
doaj   +1 more source

C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy

Journal of Diabetes Research, 2016
Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4
Sevin Demir, Sule Temizkan, Mehmet Sargin   +2 more
doaj   +1 more source

Correlations Among Glycemia and Glucose Variability, Thyroid Hormones, and Albuminuria in Patients With Type 2 Diabetes Mellitus

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo, Shang‐Yong Feng, Hui Chen, Dun‐Min She, Yan Liu, Ying Li, Cai‐Feng Yan, Zhen‐Wen Zhang, Jing Chen, Xiao‐Li Cai, Gao‐Yu Zhao, Hui Yu, Yan Wang   +12 more
wiley   +1 more source

Assessing Extracellular Vesicle Proteins as Predictive Biomarkers for Developing Type 1 Diabetes

PROTEOMICS, EarlyView.
ABSTRACT Plasma extracellular vesicles (EVs) are considered excellent sources for biomarker discovery since they carry signatures of their cellular origin and disease processes. In this paper, we evaluate the potential of plasma EV proteomics analysis for identifying predictive biomarkers of developing type 1 diabetes (T1D), which results from ...
Panshak P. Dakup, Lisa M. Bramer, Athena Schepmoes, Ivo Diaz Ludovico, Javier Flores, Raghavendra G. Mirmira, Bobbie‐Jo M. Webb‐Robertson, Thomas O. Metz, Emily K. Sims, Ernesto S. Nakayasu   +9 more
wiley   +1 more source

Porous Organic Polymers: From Molecular Design to Scalable Technologies

Small, EarlyView.
This review introduces porous organic polymers (POPs) for a wide range of applications, including energy storage, gas adsorption, catalysts, adsorbents, biomedical applications, sensors, and other exciting fields, and critically analyzes the synthesis and modification, and how structural topology influences the composites' architecture of POPs, along ...
Hossein Mashhadimoslem, Hadi Shayesteh, Simindokht Zarei‐Shokat, Rokhsareh Bakhtiari, Sheyda Abedi‐Banaei, Zahra Sheikhlouiharzand, Parnia Mohebimanesh, Seyed Mohammad Amin Ojagh, Bahareh Bakhtiari, Ali Maleki, Theo G. M. van de Ven, Sohrab Zendehboudi, Ali Elkamel   +12 more
wiley   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2013
Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj  

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Sitagliptin a DPP 4 Inhibitor

International Journal for Research Trends and Innovation, 2023
Purvita Laxman waghmodey, Mayur Rajkumar Raut, Manorama Namdev Naiknaware   +2 more
openaire   +1 more source